Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hypersensitivity Reaction
  Free Subscription

Articles published in
Eur J Dermatol
    February 2024
  1. FUKUDA H, Aoki S, Harada Y, Matsumoto C, et al
    A case of acute generalized exanthematous pustulosis caused by eperisone hydrochloride.
    Eur J Dermatol. 2024;34:97-98.
    >> Share

  2. OUNI B, Mansour K, Sassi M, Sriha B, et al
    Silodosin-induced leukocytoclastic vasculitis: a first case report.
    Eur J Dermatol. 2024;34:92-93.
    >> Share

  3. GIMENEZ-ARNAU AM, Salman A, Podder I
    Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
    Eur J Dermatol. 2024;34:3-12.
    >> Share

    December 2023
  4. DE GREEF A, Ghislain PD, Baeck M
    Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis.
    Eur J Dermatol. 2023;33:707-709.
    >> Share

  5. NISHIYORI R, Sakai T, Nishida H, Hatano Y, et al
    An unusual case of immediate and delayed hypersensitivity to wasp stings.
    Eur J Dermatol. 2023;33:701-703.
    >> Share

  6. TSAI YC, Tsai TF
    Successful treatment of atopic dermatitis by switching from upadacitinib to abrocitinib: a case report.
    Eur J Dermatol. 2023;33:699-701.
    >> Share

  7. MIYAWAKI K, Nakashima C, Otsuka A
    Real-world effectiveness and safety of nemolizumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.
    Eur J Dermatol. 2023;33:691-692.
    >> Share

  8. LAMOLET M, Barbarin C, Renaud O, Sahin Y, et al
    Acceleration of cutaneous T-cell lymphoma mistaken for atopic dermatitis following JAK inhibitor use.
    Eur J Dermatol. 2023;33:686-687.
    >> Share

  9. COHEN E, Lheure C, Ingen-Housz-Oro S, Hotz C, et al
    Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients.
    Eur J Dermatol. 2023;33:680-685.
    >> Share

    October 2023
  10. MURRAY C, Ridge K, Conlon N
    Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria.
    Eur J Dermatol. 2023;33:561-562.
    >> Share

  11. NISHITANI K, Nakajima S, Miyake T, Kaku Y, et al
    Cutaneous sarcoidosis concomitant with xanthoma on the face.
    Eur J Dermatol. 2023;33:559-561.
    >> Share

  12. KAMADA H, Arakawa N, Fukui R, Tanji T, et al
    Nemolizumab-induced drug eruption in a 46-year-old male patient with atopic dermatitis.
    Eur J Dermatol. 2023;33:558-559.
    >> Share

  13. FIGUEIREDO C, Matos AL, Cardoso JC
    Bilateral periorbital swelling as the presenting manifestation of recurrent breast carcinoma.
    Eur J Dermatol. 2023;33:551-553.
    >> Share

  14. ZHENG H, Chen Y, Xu Y, Deng X, et al
    Efficacy and safety of abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: update of a living systematic review and meta-analysis.
    Eur J Dermatol. 2023;33:530-543.
    >> Share

  15. LUGER T, Chu CY, Elgendy A, Ibrahim SBBK, et al
    Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children and sensitive skin areas.
    Eur J Dermatol. 2023;33:474-486.
    >> Share

    August 2023
  16. YAMADA M, Furuta M, Fujimoto N
    Erythema multiforme major induced by tramadol.
    Eur J Dermatol. 2023;33:437-439.
    >> Share

  17. TOYOSHIMA M, Nakaoji K, Hamada K, Yamanaka A, et al
    Analysis of skin aging patterns using a facial imaging system in patients with atopic dermatitis.
    Eur J Dermatol. 2023;33:383-393.
    >> Share

  18. ESCALANTE A, Serra-Baldrich E
    Pathogenic mechanisms underlying itch in atopic dermatitis: the emerging role of neuroimmune interactions.
    Eur J Dermatol. 2023;33:343-349.
    >> Share

  19. YU YY, Li JX, Zeng YP
    Scientific landscape and trend analysis of chronic urticaria: a two-decade bibliometric review.
    Eur J Dermatol. 2023;33:404-412.
    >> Share

  20. UOZUMI T, Serizawa N, Hagino T, Morita T, et al
    Dietary habits in Japanese patients with bullous pemphigoid: low intake of retinol.
    Eur J Dermatol. 2023;33:394-403.
    >> Share

    April 2023
  21. KOMAKI R, Miyagaki T, Okano T, Takeuchi S, et al
    Decreased serum placental growth factor levels in adult atopic dermatitis: a preliminary study.
    Eur J Dermatol. 2023;33:185-186.
    >> Share

  22. MATOS PR, Nogueira A, Gomes N, Pedrosa A, et al
    Acute generalized exanthematous pustulosis secondary to mianserin with liver involvement.
    Eur J Dermatol. 2023;33:172-174.
    >> Share

  23. DEYDIER N, Salvado M, Planes M, Misery L, et al
    Atopic dermatitis in 15q24 microdeletion syndrome: a social media study.
    Eur J Dermatol. 2023;33:157-159.
    >> Share

  24. PATSATSI A, Vakirlis E, Kanelleas A, Stefanaki I, et al
    Effect of a novel "emollient plus" formulation on mild-to-severe atopic dermatitis and other dry skin-related diseases as monotherapy or adjunctive therapy: an observational study on efficacy, tolerance and quality of life in adult patients.
    Eur J Dermatol. 2023;33:137-146.
    >> Share

  25. LI JX, Zeng YP
    Research interest in the usage of dupilumab for atopic dermatitis: a bibliometric analysis.
    Eur J Dermatol. 2023;33:87-100.
    >> Share

    February 2023
  26. MOSNIER A, Vocanson M, Lefevre MA
    Molecular profiling of skin test-induced inflammation to support the clinical diagnosis of delayed drug hypersensitivity reaction.
    Eur J Dermatol. 2023;33:64-66.
    >> Share

  27. LAMOUROUX C, Bertolotti-Potachin L, Charbotel B, Nosbaum A, et al
    Allergic contact dermatitis to diclofenac gel due to propylene glycol sensitization: usefulness of repeated open application tests to determine safer alternatives.
    Eur J Dermatol. 2023;33:42-43.
    >> Share

    November 2022
  28. ELDANI C, Darrigade AS, Beylot-Barry M, Jullie ML, et al
    Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as "toxic epidermal necrolysis-like".
    Eur J Dermatol. 2022;32:805-807.
    >> Share

  29. KOSAKA K, Uchiyama A, Ishikawa M, Watanabe G, et al
    Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study.
    Eur J Dermatol. 2022;32:800-802.
    >> Share

  30. KIM J, Choi S, Choi S, Lee YI, et al
    Contact hypersensitivity and Demodex mite infestation in patients with rosacea: a retrospective cohort analysis.
    Eur J Dermatol. 2022;32:716-723.
    >> Share

  31. SALOMON G, Giordano-Labadie F
    Surfactant irritations and allergies.
    Eur J Dermatol. 2022;32:677-681.
    >> Share

    September 2022
  32. HONDA R, Suenaga A, Nakahara T, Shibata-Kikuchi S, et al
    Atopic dermatitis refractory to dupilumab but markedly responsive to baricitinib.
    Eur J Dermatol. 2022;32:649-650.
    >> Share

  33. STEFANOU G, Gregoriou S, Kontodimas S, Sfaelos K, et al
    Prevalence of adult self-reported atopic dermatitis in Greece: results from a nationwide survey.
    Eur J Dermatol. 2022;32:597-606.
    >> Share

  34. MELE-NINOT G, Serra-Baldrich E, Spertino J, Guilarte M, et al
    Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
    Eur J Dermatol. 2022;32:629-631.
    >> Share

  35. SALONEN J, Remitz A, Salonen J, Lauerma A, et al
    Allergic conjunctivitis: a risk factor for recurrent herpes simplex virus infections in patients with atopic dermatitis.
    Eur J Dermatol. 2022;32:607-614.
    >> Share

  36. TIOTIU A, Jaussaud R
    Successful treatment with omalizumab for cold urticaria in a patient with chronic hepatitis C virus infection.
    Eur J Dermatol. 2022;32:640-641.
    >> Share

  37. TETART F, Gonde H, Hervouet C
    Do generic drugs cause hypersensitivity?
    Eur J Dermatol. 2022;32:571-576.
    >> Share

    July 2022
  38. PIOTIN A, Hacard F, Crumbach L, Nicolas JF, et al
    Anaphylaxis to chlorhexidine after taking oral medication
    Eur J Dermatol. 2022;32:551-553.
    >> Share

  39. BRAUN C, Patra V, Lina G, Nicolas JF, et al
    The role of skin dysbiosis in atopic dermatitis
    Eur J Dermatol. 2022;32:439-444.
    >> Share

  40. WOLLENBERG A, Lio P, Kleyn E, Bissonnette R, et al
    Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials
    Eur J Dermatol. 2022;32:522-529.
    >> Share

  41. SERRANO ORDONEZ A, Lopez Riquelme I, Perea Polak A
    sQuiz your knowledge! Persistent unilateral facial and lip swelling
    Eur J Dermatol. 2022;32:562-563.
    >> Share

  42. KITAYAMA S, Makino T, Kataoka K, Mori S, et al
    Valacyclovir-induced drug reaction with eosinophilia and systemic symptoms
    Eur J Dermatol. 2022;32:538-539.
    >> Share

  43. MARTINEZ-SAGUER I, Dominas N, Straben U, Greve J, et al
    Patients with hereditary angioedema and their treatment patterns in Germany: a Delphi consensus study
    Eur J Dermatol. 2022;32:487-494.
    >> Share

  44. PANKAKOSKI A, Kluger N, Sintonen H, Panelius J, et al
    Clinical manifestations and comorbidities of pemphigus: a retrospective case-control study in southern Finland
    Eur J Dermatol. 2022;32:480-486.
    >> Share

    May 2022
  45. LEFEVRE MA
    "Prick or treat": a case of systemic reaction during intradermal tests with beta-lactams
    Eur J Dermatol. 2022;32:426-428.
    >> Share

  46. FUJISHIMA C, Munemoto S, Hioki C, Sasaki H, et al
    Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia
    Eur J Dermatol. 2022;32:416-417.
    >> Share

  47. NAKAGAWA M, Hanada M, Amano H
    Allergic contact stomatitis caused by (meth)acrylates following sensitization by artificial nails, 20 years previously
    Eur J Dermatol. 2022;32:413-415.
    >> Share

  48. ROLO DE MATOS P, Nogueira A, Gomes N, Costa C, et al
    Rare presentation of Wells syndrome mimicking angioedema: a case report
    Eur J Dermatol. 2022;32:411-413.
    >> Share

  49. ULDAHL A, Sterner T, Bruze M, Dahlin J, et al
    Atopy patch testing and associations with atopic conditions and specific IgE tests: a population-based study in adolescents
    Eur J Dermatol. 2022;32:384-393.
    >> Share

  50. GUILLON C, Meziani M, Abdelli S, Sigaudo Roussel D, et al
    The aryl hydrocarbon receptor pathway plays a central role in the cutaneous response to pollutants
    Eur J Dermatol. 2022;32:305-311.
    >> Share

    April 2022
  51. SCHUSTER B, Ziehfreund S, Schielein MC, Tizek L, et al
    Adding happiness to complement the Dermatology Quality of Life Index in psoriasis and atopic dermatitis healthcare: a cross-sectional study
    Eur J Dermatol. 2022;32:220-226.
    >> Share

  52. MASUDA K, Delozier AM, Kolodsick J, Buchanan A, et al
    Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysi
    Eur J Dermatol. 2022;32:237-243.
    >> Share

  53. STEFANIAK AA, Knecht K, Matusiak L
    sQuiz your knowledge! Non-pruritic chronic urticaria and recurrent episodes of fever
    Eur J Dermatol. 2022;32:300-301.
    >> Share

    February 2022
  54. VAN HALEWIJN KF, Lahnstein T, Bohnen AM, Van Den Berg PJ, et al
    Recommendations for emollients, bathing and topical corticosteroids for the treatment of atopic dermatitis: a systematic review of guidelines.
    Eur J Dermatol. 2022 Feb 21. pii: ejd.2022.4197. doi: 10.1684/ejd.2022.4197.
    >> Share

  55. NADA HR, Rashed LA, Shehada J, Mostafa PIN, et al
    Phosphodiesterase 4 (PDE4) gene expression in atopic dermatitis patients, before and after treatment with topical mometasone cream.
    Eur J Dermatol. 2022 Feb 15. pii: ejd.2022.4194. doi: 10.1684/ejd.2022.4194.
    >> Share

  56. ESCURE G, Nudel M, Terriou L, Farhat MM, et al
    Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.
    Eur J Dermatol. 2022;32:49-55.
    >> Share

    January 2022
  57. LEFEVRE MA, Mosnier A
    A case of paracetamol-induced nonpigmented fixed drug eruption confirmed by a lymphocyte transformation test.
    Eur J Dermatol. 2022;32:154-156.
    >> Share

  58. SHEN X, Zhang W, Li X, Lu H, et al
    Association between serum IgG and Henoch-Schonlein purpura with renal involvement in children: a cross-sectional study.
    Eur J Dermatol. 2022;32:132-134.
    >> Share

    December 2021
  59. SALAVA A, Perala M, Juppo M, Pelkonen AS, et al
    Effective treatment of atopic dermatitis in small children significantly improves the quality of life of patients and their families.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4169. doi: 10.1684/ejd.2021.4169.
    >> Share

  60. EGEBERG A, Anderson P, Piercy J, Massey L, et al
    Symptom burden of patients with moderate-to-severe atopic dermatitis.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4166. doi: 10.1684/ejd.2021.4166.
    >> Share

  61. LORET L, Ninclaus V, Dendooven A, Lapeere H, et al
    Canalicular stenosis associated with dupilumab treatment for atopic dermatitis.
    Eur J Dermatol. 2021 Dec 17. pii: ejd.2021.4180. doi: 10.1684/ejd.2021.4180.
    >> Share

  62. CHESTER J, Kaleci S, Liberati S, Alicandro T, et al
    Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis.
    Eur J Dermatol. 2021 Dec 15. pii: ejd.2021.4168. doi: 10.1684/ejd.2021.4168.
    >> Share

  63. LEFEVRE MA, Mohme S, Alband N, Nogueira M, et al
    Journal club: New small molecules for atopic dermatitis management.
    Eur J Dermatol. 2021;31:849-852.
    >> Share

  64. TRAIDL S, Heratizadeh A, Werfel T, Dressler C, et al
    Online survey to identify current challenges in atopic dermatitis management and guideline implementation in German-speaking countries.
    Eur J Dermatol. 2021;31:806-812.
    >> Share

  65. ROVATI C, Rossi M, Gelmetti A, Tomasi C, et al
    Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients.
    Eur J Dermatol. 2021;31:736-740.
    >> Share

  66. RAVAL NS, Snowden CK, De Monnin KS, Yokoyama CC, et al
    Scarring alopecia developing after mogamulizumab-associated rash.
    Eur J Dermatol. 2021;31:841-843.
    >> Share

  67. SUKAKUL T, Svedman C, Dahlin J, Bergendorff O, et al
    Simultaneous positive patch test reactions to neomycin and low-molecular-weight heparins: possible cross-reaction?
    Eur J Dermatol. 2021;31:741-743.
    >> Share

    October 2021
  68. KURIHARA K, Fujiyama T, Tokura Y, Honda T, et al
    Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
    Eur J Dermatol. 2021 Oct 26. pii: ejd.2021.4140. doi: 10.1684/ejd.2021.4140.
    >> Share

  69. KHELLAF L, Cosserat J, Calas A, Brasme H, et al
    Unusual neurological and cardiac complications of drug reaction with eosinophilia and systemic symptoms syndrome: a case report.
    Eur J Dermatol. 2021;31:652-654.
    >> Share

  70. FANG YH, Wei KC, Yu MS
    Improvement of erythema elevatum diutinum refractory to dapsone following treatment for underlying multiple myeloma.
    Eur J Dermatol. 2021;31:655-657.
    >> Share

    August 2021
  71. INGEN-HOUSZ-ORO S, Staumont-Salle D, Palladini A, Ferries L, et al
    Immunosuppressants as steroid-sparing agents for chronic DRESS: four cases.
    Eur J Dermatol. 2021;31:576-577.
    >> Share

    June 2021
  72. LEFEVRE MA, Nosbaum A
    Dermpath and Clinic: How to manage adverse reactions to biological agents.
    Eur J Dermatol. 2021;31:426-427.
    >> Share

  73. CUI Y, Shi J, Wang C, Vinturache A, et al
    Therapeutic plasma exchange combined with continuous venovenous hemofiltration in a series of pediatric patients with toxic epidermal necrolysis.
    Eur J Dermatol. 2021;31:413-415.
    >> Share

  74. WATABE D, Amano H
    TNF-alpha inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis.
    Eur J Dermatol. 2021;31:412-413.
    >> Share

  75. PERRON E, Viarnaud A, Marciano L, Karkouche R, et al
    Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms.
    Eur J Dermatol. 2021;31:372-380.
    >> Share

  76. SUGINO H, Nakamura M
    Mild hypertrichosis in both upper arms around dupilumab injection sites.
    Eur J Dermatol. 2021;31:420-421.
    >> Share

    April 2021
  77. MORIMOTO H, Fukuchi K, Ogura Y, Ohtsuka M, et al
    Development of lichen planus following benralizumab treatment.
    Eur J Dermatol. 2021 Apr 2. pii: ejd.2021.3995. doi: 10.1684/ejd.2021.3995.
    >> Share

  78. GIORDANO-LABADIE F, Becherel PA, Pralong P, Outtas O, et al
    Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Eur J Dermatol. 2021;31:217-224.
    >> Share

    March 2021
  79. KIRSTEN N, Mohr N, Maul JT, Augustin M, et al
    Incidence of atopic conditions in people with psoriasis: a population-based analysis.
    Eur J Dermatol. 2021 Mar 1. pii: ejd.2021.3963. doi: 10.1684/ejd.2021.3963.
    >> Share

    February 2021
  80. BELBEZIER A, Boccon-Gibod I, Bouillet L
    Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Eur J Dermatol. 2021;31:86-87.
    >> Share

  81. KOMATSU-FUJII T, Ogawa M, Nonoyama S, Fukumoto T, et al
    Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1(R)) after nivolumab discontinuation.
    Eur J Dermatol. 2021;31:98-99.
    >> Share

  82. KUMANO Y, Nagai A, Sugiura K
    Erythro-papular type drug eruption caused by fosravuconazole L-lysine ethanolate.
    Eur J Dermatol. 2021;31:90-91.
    >> Share

  83. UGAJIN T, Namiki T, Yokozeki H
    A case of prurigo caused by hair dye containing p-phenylenediamine: histopathological findings.
    Eur J Dermatol. 2021;31:103-104.
    >> Share

  84. MAKIHARA-INUKAI M, Takeichi T, Ogawa-Momohara M, Muro Y, et al
    Morphea in a Crohn's disease patient undergoing ustekinumab treatment.
    Eur J Dermatol. 2021;31:96-97.
    >> Share

  85. FAUCON C, Bernigaud C, Sbidian E, Hue S, et al
    Essential oils as potential triggers for bullous pemphigoid? A report of two patients.
    Eur J Dermatol. 2021;31:92-93.
    >> Share

  86. HAYAMA K, Fujita H, Asai-Sato M, Kawana K, et al
    Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Eur J Dermatol. 2021;31:100-101.
    >> Share

    January 2021
  87. NAGASAWA Y, Iinuma S, Fujii M, Kanno K, et al
    Dasatinib-induced panniculitis in a patient with chronic myeloid leukaemia.
    Eur J Dermatol. 2021 Jan 25. pii: ejd.2020.3946. doi: 10.1684/ejd.2020.3946.
    >> Share

  88. COSTEDOAT I, Vergara R, Dousset L, Gerard E, et al
    Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod.
    Eur J Dermatol. 2021 Jan 15. pii: ejd.2020.3951. doi: 10.1684/ejd.2020.3951.
    >> Share

    December 2020
  89. DANSET M, Hacard F, Jaulent C, Nosbaum A, et al
    Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Eur J Dermatol. 2020 Dec 18. pii: ejd.2020.3910. doi: 10.1684/ejd.2020.3910.
    >> Share

    November 2020
  90. KIMURA R, Sugita K, Yamamoto O
    Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Eur J Dermatol. 2020 Nov 24. pii: ejd.2020.3904. doi: 10.1684/ejd.2020.3904.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016